# LUCAS (Lucentis Compared to Avastin Study)

> **NCT01127360** · PHASE4 · COMPLETED · sponsor: **Oslo University Hospital** · enrollment: 420 (actual)

## Conditions studied

- Exudative Age-related Macular Degeneration

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Ranibizumab

## Key facts

- **NCT ID:** NCT01127360
- **Lead sponsor:** Oslo University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03
- **Primary completion:** 2014-08
- **Final completion:** 2014-08
- **Target enrollment:** 420 (ACTUAL)
- **Last updated:** 2015-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01127360

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01127360, "LUCAS (Lucentis Compared to Avastin Study)". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01127360. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*